Home > Protocol Summaries: Compounds > GSK239512 Protocol Summaries: GSK239512 GSKStudy ID Phase Title Status 110651 phase 2 A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of the H3 receptor antagonist, GSK239512 in subjects with mild to moderate Alzheimer’s disease. Completed 113147 phase 2 A randomised double-blind, placebo controlled, parallel group study to evaluate the cognitive enhancing effect of GSK239512 in stable patients with schizophrenia Completed 116477 phase 2 Proof of Mechanism Study to Assess the Potential of GSK239512 to Remyelinate Lesions in Subjects with Relapsing Remitting Multiple Sclerosis Recruiting 117016 phase 1 An Open Label Study in Healthy Volunteers to Investigate the Effect of Ketoconazole on the Pharmacokinetics of GSK239512 Completed H3B106026 Phase 1 A PET study using [11C] GSK189254 to establish the dose, plasma concentration and brain receptor occupancy relationship of GSK239512, a histamine H3 antagonist, in healthy subjects Completed H3B109689 phase 1 A single blind, placebo-controlled, randomised study in mild to moderate Alzheimer’s disease patients to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK239512, a selective histamine H3 receptor antagonist Completed
